AC Immune, a Swiss biotech developing therapies for Alzheimer's, partnered with Genentech, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. AC Immune plans to list on the Nasdaq under the symbol ACIU. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal.
